Home | Login
MASC - Melanoma and Skin Cancer Trials

Melanoma and Skin Cancer Trials

Limited

 

LOGIN



Please enter your username and password.


Username

Password


  
ANZMTG
 

Closed Trials

ANZMTG 01.02 - Adjuvant Radiotherapy Trial

The use of radiotherapy after therapeutic lymphadenectomy for patients with melanoma at high risk of further lymph-node field and distant recurrence is controversial.

This is the first completed study to assess the effects of RT on regional recurrence, survival, morbidity and quality of life (QOL) in these patients.


01.07 SS01.13 - The Hair Spare Study

Whole Brain Radiotherapy (WBRT) is a common palliative treatment for brain metastases (BMs). WBRT is traditionally given with opposed lateral fields. With this technique, the hair bearing scalp skin receives the full dose, resulting in acute epilation often leading to alopecia, so decreasing quality of life (QoL). VMAT HSWBRT is the acronym for volumetric modulated arc therapy hair sparing whole brain radiotherapy. VMAT may allow hair sparing (HS) when delivering WBRT. This study will investigate whether VMAT HSWBRT can minimise acute epilation while delivering effective WBRT, thereby improving QoL.


ANZMTG 02.09 Mel-D Trial - Vitamin D following primary treatment of melanoma at high risk of recurrence

There is currently no high evidence to show that Vitamin D can improve melanoma prognosis. This is a pilot phase II study which aims to  determine whether administration of a loading oral dose of 500,000 IU of Vitamin D followed by a monthly oral dose of 50,000 IU of Vitamin D for 2 years following primary treatment of melanoma at high risk of recurrence.


ANZMTG 03.17 Improving skin cancer prevention: motivating preventive behaviours using knowledge of personalised genomic risk of melanoma


ANZMTG - MSLT II

A phase III multicenter randomised trial of sentinel lymphadenectomy and complete lymph node dissection versus sentinel lyphadenectomy alone, in cutaneous melanoma patients with molecular or histopathological evidence of metastases in the sentinel node (MSLT II).


ANZMTG 01.13 Trial - A randomised controlled trial of a psycho-educational intervention for melanoma survivors at high risk of developing new primary disease

There are very few psychosocial resources designed to address the information and support needs of melanoma patients. This randomised controlled clinical trials  aims to evaluate the efficacy of a psycho-educational intervention in reducing fear of melanoma recurrence (defined in this study as fear of melanoma recurrence as well as fear of developing new primary disease) in melanoma survivors at high risk of developing new primary melanoma, compared to usual care.


Return to Trials main page.